ADAR1 Capital Management LLC Makes New Investment in Climb Bio, Inc. $CLYM

Key Points

• ADAR1 Capital Management LLC acquired 119,320 shares of Climb Bio, Inc., worth approximately $146,000, representing 0.18% of the company's stock at the end of the recent quarter.
• Climb Bio has received an "outperform" rating from analysts, with price targets set between $9.00 and $10.00, indicating strong potential for growth in its stock value.
• Climb Bio reported an earnings per share (EPS) of ($0.13) for the last quarter, beating the consensus estimate, and is focused on developing therapeutics for immune-mediated diseases.

ADAR1 Capital Management LLC bought a new position in shares of Climb Bio, Inc. (NASDAQ:CLYM - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 119,320 shares of the company's stock, valued at approximately $146,000. ADAR1 Capital Management LLC owned 0.18% of Climb Bio at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. RA Capital Management L.P. acquired a new stake in Climb Bio during the first quarter worth approximately $38,332,000. Affinity Asset Advisors LLC acquired a new stake in Climb Bio during the first quarter worth approximately $1,830,000. Peapod Lane Capital LLC acquired a new stake in Climb Bio during the first quarter worth approximately $676,000. Persistent Asset Partners Ltd acquired a new stake in Climb Bio during the first quarter worth approximately $178,000. Finally, TD Asset Management Inc acquired a new stake in Climb Bio during the first quarter worth approximately $109,000. Institutional investors and hedge funds own 69.76% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on CLYM. BTIG Research began coverage on Climb Bio in a report on Thursday, May 22nd. They issued a "buy" rating on the stock. Baird R W upgraded Climb Bio to a "strong-buy" rating in a report on Friday, August 15th. Oppenheimer began coverage on Climb Bio in a report on Friday, June 6th. They issued an "outperform" rating and a $10.00 price target on the stock. Finally, Robert W. Baird began coverage on Climb Bio in a report on Friday, August 15th. They issued an "outperform" rating and a $9.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating and four have issued a Buy rating to the company. Based on data from MarketBeat, Climb Bio presently has a consensus rating of "Buy" and a consensus target price of $9.00.

Climb Bio Trading Up 4.2%

Shares of NASDAQ:CLYM traded up $0.10 during mid-day trading on Monday, hitting $2.49. 401,772 shares of the company traded hands, compared to its average volume of 358,767. The stock has a market cap of $168.72 million, a P/E ratio of -3.56 and a beta of -0.05. Climb Bio, Inc. has a 12-month low of $1.05 and a 12-month high of $8.79. The stock has a 50-day moving average price of $1.72 and a two-hundred day moving average price of $1.43.

Climb Bio (NASDAQ:CLYM - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.06. As a group, analysts expect that Climb Bio, Inc. will post -1.57 earnings per share for the current year.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.